Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Ly-6G Rat anti-Mouse, BUV395, Clone: 1A8, BD

Rat Monoclonal Antibody

Manufacturer:  BD Biosciences 563978

Catalog No. BDB563978


Add to cart

Description

Description

The 1A8 monoclonal antibody specifically binds to Ly-6G, a 21-25-kDa glycosyolphosphatidylinositol-anchored protein. In the bone marrow, Ly-6G is expressed on the majority of the largest cells, which are predominantly granulocytes, and not on lymphoid or erythroid cells. In the periphery, it is expressed on granulocytes. The RB6-8C5 monoclonal antibody recognizes both Ly-6G and Ly-6C and blocks the binding of mAb 1A8 to Ly-6G.

The antibody was conjugated to BD Horizon™ BUV395 which has been exclusively developed by BD Biosciences as an optimal dye for use on a 355nm laser equipped instrument. With an Ex Max at 348 nmand an Em Max at 395nm, this dye has virtually no spillover into any other detector. BD Horizon™ BUV395 can be excited with a 355nm laser and detected with a 379/28 filter.

Specifications

Specifications

Ly-6G
1A8
Brilliant Ultraviolet 395
Aqueous buffered solution containing BSA and ≤0.09% sodium azide.
Rat
IgG2a, κ
RUO
Primary
Murine
Flow Cytometry
0.2mg/mL
Ly6g; Lymphocyte antigen 6G; Lymphocyte antigen 6 complex, locus G; Gr1
Affinity Purified
Ly-6G-transfected EL4J cell line
50μg
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.
Monoclonal
Documents
Provide Content Correction

We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Cancel Submit